Sharpen Your Sword for Litigation: Incumbent Strategic Reaction to the Threat of Entry

References

• Adams CP, Brantner VV (2006) Estimating the cost of new drug development: Is it really $802 million? Health Affairs 25(2):420–428.Crossref, Google Scholar
• Bair SP (2013) Adjustments, extensions, disclaimers, and continuations: When do patent term adjustments make sense. Capital Univ. Law Rev. 41:445.Google Scholar
• Berndt ER, Aitken ML (2011) Brand loyalty, generic entry and price competition in pharmaceuticals in the quarter century after the 1984 Waxman-Hatch legislation. Internat. J. Econom. Bus. 18(2):177–201.Google Scholar
• Branstetter L, Chatterjee C, Higgins MJ (2016) Regulation and welfare: Evidence from Paragraph IV generic entry in the pharmaceutical industry. RAND J. Econom. 47(4):857–890.Crossref, Google Scholar
• Branstetter L, Chatterjee C, Higgins MJ (2022) Starving (or fattening) the golden goose? Generic entry and the incentives for earlystage pharmaceutical innovation. Working paper, Carnegie Mellon University, Pittsburgh.Google Scholar
• Bulow J (2004) The gaming of pharmaceutical patents. Innovation Policy Econom. 4:145–187.Crossref, Google Scholar
• Bulow JI, Geanakoplos JD, Klemperer PD (1985) Multimarket oligopoly: Strategic substitutes and complements. J. Political Econom. 93(3):488–511.Crossref, Google Scholar
• Ceccagnoli M (2009) Appropriability, preemption, and firm performance. Strategic Management J. 30(1):81–98.Crossref, Google Scholar
• Cockburn IM, MacGarvie MJ (2011) Entry and patenting in the software industry. Management Sci. 57(5):915–933.Link, Google Scholar
• Cohen WM, Nelson RR, Walsh JP (2000) Protecting their intellectual assets: Appropriability conditions and why U.S. manufacturing firms patent (or not). NBER Working Paper No. 7552, National Bureau of Economic Research, Cambridge, MA.Google Scholar
• Conti R, Valentini G (2018) Super partes? Assessing the effect of judicial independence on entry. Management Sci. 64(8):3517–3535.Link, Google Scholar
• Cookson JA (2018) Anticipated entry and entry deterrence: Evidence from the American casino industry. Management Sci. 64(5):2325–2344.Link, Google Scholar
• De Rassenfosse G (2018) Notice failure revisited: Evidence on the use of virtual patent marking. NBER Working Paper No. 24288, National Bureau of Economic Research, Cambridge, MA.Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG, Lasagna L (1991) Cost of innovation in the pharmaceutical industry. J. Health Econom. 10(2):107–142.Crossref, Google Scholar
• Dixit A (1980) The role of investment in entry-deterrence. Econom. J. (London) 90(357):95–106.Google Scholar
• Dogan SL, Lemley MA (2008) Antitrust law and regulatory gaming. Texas Law Rev. 87(4):685.Google Scholar
• Drake KM, He R, McGuire TG, Ndikumana A (2022) No free launch: At-risk entry by generic drug firms. Internat. J. Econom. Bus. 29(3):301–315.Google Scholar
• Durvasula M, Hemphill CS, Ouellette LL, Sampat B, Williams HL (2023) The NBER orange book data set: A user’s guide. Res. Policy 52(7):104791.Crossref, Google Scholar
• Ellison G, Ellison SF (2011) Strategic entry deterrence and the behavior of pharmaceutical incumbents prior to patent expiration. Amer. Econom. J. Microeconomics 3(1):1–36.Crossref, Google Scholar
• Federal Trade Commission (2002) Generic Drug Entry Prior to Patient Expiration: An FTC Study (U.S. Government Printing Office, Washington, DC).Google Scholar
• Federal Trade Commission (2009) Authorized Generic Drugs: An Interim Report (U.S. Government Printing Office, Washington, DC).Google Scholar
• Federal Trade Commission (2011) Authorized Generic Drugs: Short-Term Effects and Long-Run Impacts (U.S. Government Printing Office, Washington, DC).Google Scholar
• Filson D, Oweis A (2010) The impacts of the rise of Paragraph IV challenges on startup alliance formation and firm value in the pharmaceutical industry. J. Health Econom. 29(4):575–584.Crossref, Google Scholar
• Friedman JN (2009) The Incidence of the Medicare Prescription Drug Benefit: Using Asset Prices to Assess Its Impact on Drug Makers (Harvard University, Cambridge, MA).Google Scholar
• Fromer JC (2016) Dynamic patent disclosure. Vanderbilt Law Rev. 69(6):1715.Google Scholar
• Fudenberg D, Tirole J (1984) The fat-cat effect, the puppy-dog ploy, and the lean and hungry look. Amer. Econom. Rev. 74(2):361–366.Google Scholar
• Gaessler F, Wagner S (2022) Patents, data exclusivity, and the development of new drugs. Rev. Econom. Statist. 104(3):571–586.Crossref, Google Scholar
• Gambardella A (2013) The economic value of patented inventions: Thoughts and some open questions. Internat. J. Indust. Organ. 31(5):626–633.Crossref, Google Scholar
• Gilbert RJ, Newbery DM (1982) Preemptive patenting and the persistence of monopoly. Amer. Econom. Rev. 72(3):514–526.Google Scholar
• Glass G (2021) The Paragraph Four Book (Parry Ashford, Tampa, FL).Google Scholar
• Goodman-Bacon A (2021) Difference-in-differences with variation in treatment timing. J. Econometrics 225(2):254–277.Crossref, Google Scholar
• Grabowski H (2007) Competition between generic and branded drugs. Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International (Cambridge University Press, Cambridge, MA), 153–173.Google Scholar
• Grabowski HG, Kyle M (2007) Generic competition and market exclusivity periods in pharmaceuticals. Management Decision Econom. 28(4–5):491–502.Crossref, Google Scholar
• Grabowski H, Vernon J (1996) Longer patents for increased generic competition in the US. PharmacoEconomics 10(2):110–123.Crossref, Google Scholar
• Graham SJ, Mowery DC (2004) Submarines in software? Continuations in US software patenting in the 1980s and 1990s. Econom. Innovation New Tech. 13(5):443–456.Crossref, Google Scholar
• Gupta C (2023) One product, many patents: Imperfect intellectual property rights in the pharmaceutical industry. Working paper, UCLA, Los Angeles.Google Scholar
• Hall BH, Ziedonis RH (2001) The patent paradox revisited: An empirical study of patenting in the US semiconductor industry, 1979–1995. RAND J. Econom. 32(1):101–128.Crossref, Google Scholar
• Hegde D, Mowery DC, Graham SJ (2009) Pioneering inventors or thicket builders: Which US firms use continuations in patenting? Management Sci. 55(7):1214–1226.Link, Google Scholar
• Hemphill CS, Sampat BN (2011) When do generics challenge drug patents? J. Empirical Legal Stud. 8(4):613–649.Crossref, Google Scholar
• Higgins MJ, Graham SJ (2009) Balancing innovation and access: Patent challenges tip the scales. Science 326(5951):370–371.Crossref, Google Scholar
• Higgins MJ, Rodriguez D (2006) The outsourcing of R&D through acquisitions in the pharmaceutical industry. J. Financial Econom. 80(2):351–383.Crossref, Google Scholar
• Hollis A (2001) Closing the FDA’s Orange Book. Regulation 24:14.Google Scholar
• Holovac MA (2004) A balancing act in the United States drug industry: Pioneer and generic drugs, the Orange Book, marketing protection and the US consumer. World Patent Inform. 26(2):123–129.Crossref, Google Scholar
• Jacobo-Rubio R, Turner JL, Williams JW (2020) The distribution of surplus in the US pharmaceutical industry: Evidence from Paragraph IV patent-litigation decisions. J. Law Econom. 63(2):203–238.Crossref, Google Scholar
• Krieger J, Li X, Thakor RT (2022) Find and replace: R&D investment following the erosion of existing products. Management Sci. 68(9):6552–6571.Link, Google Scholar
• Lemley MA, Moore KA (2004) Ending abuse of patent continuations. Boston Univ. Law Rev. 84:63.Google Scholar
• Lemley MA, Shapiro C (2005) Probabilistic patents. J. Econom. Perspect. 19(2):75–98.Crossref, Google Scholar
• Lieberman MB, Montgomery DB (1998) First-mover (dis)advantages: Retrospective and link with the resource-based view. Strategic Management J. 19(12):1111–1125.Crossref, Google Scholar
• Morton FMS (1999) Entry decisions in the generic pharmaceutical industry. RAND J. Econom. 30(3):421–440.Crossref, Google Scholar
• Myers K, Pauly M (2019) Endogenous productivity of demand-induced R&D: Evidence from pharmaceuticals. RAND J. Econom. 50(3):591–614.Crossref, Google Scholar
• Palermo V, Higgins MJ, Ceccagnoli M (2019) How reliable is the market for technology? Rev. Econom. Statist. 101(1):107–120.Crossref, Google Scholar
• Panattoni LE (2011) The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms. J. Health Econom. 30(1):126–145.Crossref, Google Scholar
• Prince JT, Simon DH (2015) Do incumbents improve service quality in response to entry? Evidence from airlines’ on-time performance. Management Sci. 61(2):372–390.Link, Google Scholar
• Righi C (2022) Do patent continuations increase litigation? Working paper, Universitat Pompeu Fabra, Barcelona, Spain.Google Scholar
• Righi C, Simcoe T (2023) Patenting inventions or inventing patents? Continuation practice at the USPTO. RAND J. Econom. 54(3):416–442.Google Scholar
• Saha A, Grabowski H, Birnbaum H, Greenberg P, Bizan O (2006) Generic competition in the US pharmaceutical industry. Internat. J. Econom. Bus. 13(1):15–38.Google Scholar
• Seamans RC (2012) Fighting city hall: Entry deterrence and technology upgrades in cable tv markets. Management Sci. 58(3):461–475.Link, Google Scholar
• Shapiro C (2000) Navigating the patent thicket: Cross licenses, patent pools, and standard setting. Innovation Policy Econom. 1:119–150.Crossref, Google Scholar
• Teece DJ (1986) Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy. Res. Policy 15(6):285–305.Crossref, Google Scholar
• Thomas JR (2022) Noticing patents. Columbia Sci. Tech. Law Rev. 24:299.Crossref, Google Scholar
• Torrisi S, Gambardella A, Giuri P, Harhoff D, Hoisl K, Mariani M (2016) Used, blocking and sleeping patents: Empirical evidence from a large-scale inventor survey. Res. Policy 45(7):1374–1385.Crossref, Google Scholar
• Tu SS, Lemley MA (2021) What litigators can teach the Patent Office about pharmaceutical patents. Wash. UL Rev. 99:1673.Google Scholar
• Tu SS, Kesselheim AS, Wetherbee K, Feldman WB (2023) Changes in the number of continuation patents on drugs approved by the FDA. JAMA 330(5):469–470.Crossref, Google Scholar
• Voet MA (2020) The Generic Challenge: Understanding Patents, FDA and Pharmaceutical Life-CycleManagement (BrownWalker Press, Boca Raton, FL).Google Scholar
• Williams H (2018) Readme: Orange Book patent and exclusivity data. Technical report, National Bureau of Economic Research, Cambridge, MA.Google Scholar
• Ziedonis RH (2004) Don’t fence me in: Fragmented markets for technology and the patent acquisition strategies of firms. Management Sci. 50(6):804–820.Link, Google Scholar